Skin and Soft Tissue Infections

Identifying the cause of skin, surgical site, and wound infections is necessary to effectively prescribe treatment. With 50-percent methicillin-resistance in S. aureus, the need for rapid diagnostics is becoming more important for ensuring better clinical outcomes.

Currently, no means exist to accelerate the availability fo bacterial identification and antibiotic susceptibility for S. aureus in skin and soft tissue infections. MicroPhage intends to introduce the KeyPath^™ MRSA/MSSA Skin and Soft Tissue Infection Test that is designed to rapidly identify the presence of S. aureus and determine methicillin resistance (MRSA) and methicillin susceptibility (MSSA).

Using our easy-to-use bacteriophage amplification platform, the test will provide high quality results in hours without the need for expensive equipment, batching, or specialized personnel. By providing results days before traditional ID/AST results, the MicroPhage test will enable more effective treatment and improved patient care.